Skip to content
OpenCapital
Get started

AbbVie ABBV All other — Net revenues

Other product segments

Skyrizi
$4.48B+30.9%
Rinvoq
$2.12B+23.3%
Botox Therapeutic
$1.01B+16.5%
Vraylar
$905M+18.3%
Venclexta
$770M+15.8%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Imbruvica
$556M-24.7%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Vyalev
$201M+219%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

OraSure Technologies logo
OSUROther — Net revenues
$1.55M+65.8%
Columbus McKinnon Corporation logo
CMCOAll other — Net Sales
-$730K-6,736%
Cavco Industries logo
CVCOAll other sources — Net revenue
$20.35M+5.8%
ST
STAll other — Net revenue
$154.7M+15.7%
Amneal Pharmaceuticals, Inc. logo
AMRXOther — Net revenue
$7.1M+11.4%
Cumberland Pharmaceuticals logo
CPIXOther — Revenue
$1.03M+210%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's all other — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's all other — net revenues?
AbbVie (ABBV) reported all other — net revenues of $1.03B in Q1 2026.
How has AbbVie's all other — net revenues changed year-over-year?
AbbVie's all other — net revenues decreased by 18.2% year-over-year, from $1.25B to $1.03B.
What is the long-term trend for AbbVie's all other — net revenues?
Over 4 years (2021 to 2025), AbbVie's all other — net revenues has grown at a -11.1% compound annual growth rate (CAGR), from $5.02B to $3.13B.
What does all other — net revenues mean?
This metric represents the total net revenue generated by product lines or business activities that do not meet the quantitative threshold for separate reporting as a primary operating segment. It captures the aggregate performance of miscellaneous pharmaceutical offerings, legacy products, or non-core business units within the company's portfolio. Monitoring this figure helps investors understand the revenue contribution of smaller, diversified assets outside of the company's main therapeutic focus areas.